Mankind Pharma cash flow

Latest FY26

Cash from operations: ₹3,121cr+29.3% on FY25
Capital spending: ₹737cr+41.7% on FY25
Free cash flow: ₹2,384cr+25.9% on FY25
Cash from financing: −₹2,953cr₹10,290 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	886	621	398	326
	—	639	404	33.0	44.5
	—	−58.1	−67.9	−40.1	−12.8
	—	0.0	0.0	−0.0	−0.0
	—	18.2	26.6	23.2	0.0
	—	−32.0	−2.4	−3.6	4.0
	—	−165	−359	0.0	−58.7
	—	0.0	0.0	−183	8.0
	—	−50.8	−221	−55.0	262
	—	−172	−124	−290	−205
	—	−12.6	28.2	113	−129
	—	−149	−125	5.2	296
	—	210	−146	97.5	−65.0
	—	56.5	160	2.7	16.2
	—	−21.0	106	50.9	−60.4
	—	243	174	95.7	53.2
Cash from operating activities
	2,853	2,321	2,504	2,384	1,659
	—	1,393	476	248	478
	—	3,714	2,980	2,632	2,136
	—	593	567	480	323
	—	3,121	2,413	2,152	1,813
Cash from investing activities
	—	626	461	315	789
	—	111	59.3	67.0	43.0
	—	3.0	12.0	7.5	6.0
	—	0.0	8.0	0.0	0.0
	—	0.0	0.0	7.4	−6.2
	—	0.0	0.0	0.0	3.8
	—	7.8	0.0	0.0	0.0
	—	0.4	1.1	1.2	0.4
	—	0.0	0.0	0.0	0.0
	—	58.1	67.9	40.1	12.8
	—	472	−12,250	−1,753	−230
	—	−196	−12,683	−2,082	−1,054
Cash from financing activities
	—	21.5	2,963	0.0	0.0
	—	3,978	12,451	401	1,099
	—	6,218	5,073	367	1,794
	—	29.3	12.2	0.0	0.0
	—	—	—	3.3	3.0
	—	664	96.7	25.4	41.5
	—	41.3	0.0	0.0	0.0
	—	0.0	57.6	0.0	0.0
	—	−2,953	10,290	5.3	−740
	—	−27.8	20.6	76.0	19.4
	—	15.6	1.3	1.2	2.3
	—	−12.2	21.9	77.2	21.8
	—	392	—	382	305
Reference items
	4,077	3,617	3,018	2,535	1,901
	26.5%	25.3%	24.7%	24.5%	21.7%
	2,384	2,384	1,893	1,770	981
	—	−480	10,101	1,782	—
	₹57.75	₹57.75	₹45.86	₹42.88	₹23.77
	43.11×	—	—	—	—
	—	1.61×	1.20×	1.11×	1.38×
	—	593	567	480	323
	—	664	96.7	25.4	41.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MANKIND₹2,490.00

Mankind Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA CIPLA TORNTPHARM LAURUSLABS BIOCON ALKEM LUPIN GLENMARKMcap ₹1.03L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	325.9	398.3	621.2	886.2	—
+ Finance Costs	44.5	33.0	404.0	639.3	—
+ Interest Income	-12.8	-40.1	-67.9	-58.1	—
+ Dividend Income	-0.0	-0.0	0.0	0.0	—
+ Share-based Payments	0.0	23.2	26.6	18.2	—
+ Unrealised FX (Gain) / Loss	4.0	-3.6	-2.4	-32.0	—
+ Other Non-cash Items	-58.7	0.0	-359.1	-165.4	—
+ Other Reconciling Items	8.0	-183.4	0.0	0.0	—
Changes in Working Capital
+ Inventories	261.8	-55.0	-220.7	-50.8	—
+ Trade Receivables — Current	-205.3	-289.9	-123.6	-172.0	—
+ Other Financial Assets — Current	-129.3	113.3	28.2	-12.6	—
+ Other Current Assets	295.6	5.2	-125.4	-148.8	—
+ Trade Payables — Current	-65.0	97.5	-146.0	210.3	—
+ Other Financial Liabilities — Current	16.2	2.7	160.3	56.5	—
+ Other Current Liabilities	-60.4	50.9	106.5	-21.0	—
+ Provisions — Current	53.2	95.7	174.3	243.1	—
Cash from Operating Activities
Profit Before Tax (per I/S)	1,658.8	2,384.1	2,504.1	2,321.0	2,852.9
+ Total Adjustments (incl. Working Capital)	477.6	247.8	476.0	1,393.0	—
Cash from Operations (pre-tax)	2,136.4	2,632.0	2,980.1	3,714.0	—
+ Income Taxes Paid	323.1	479.5	566.8	592.7	—
Cash from Operating Activities	1,813.3	2,152.4	2,413.4	3,121.3	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	789.0	315.3	460.8	626.0	—
+ Acq of Intangible Assets	43.0	67.0	59.3	111.3	—
+ Disp of Fixed Assets	6.0	7.5	12.0	3.0	—
+ Disp of Investment Property	0.0	0.0	8.0	0.0	—
+ Disp of Interests in Joint Ventures	-6.2	7.4	0.0	0.0	—
+ Acq of Subsidiaries / Businesses (net)	3.8	0.0	0.0	0.0	—
+ Share of Profits — Partnership Firms / LLPs	0.0	0.0	0.0	7.8	—
+ Loans & Advances Made	0.4	1.2	1.1	0.4	—
+ Dividends Received — Investing	0.0	0.0	0.0	0.0	—
+ Interest Received — Investing	12.8	40.1	67.9	58.1	—
+ Other Inflows / (Outflows) — Investing	-230.4	-1,753.1	-12,249.6	472.4	—
Cash from Investing Activities	-1,054.1	-2,081.7	-12,683.0	-196.4	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	2,963.2	21.5	—
+ Proceeds from Borrowings	1,098.6	400.7	12,451.3	3,978.0	—
+ Repayment of Borrowings	1,793.8	366.7	5,073.1	6,218.0	—
+ Payment of Lease Liabilities	0.0	0.0	12.2	29.3	—
+ Payment of Finance Lease Liabilities	3.0	3.3	—	—	—
+ Interest Paid	41.5	25.4	96.7	663.6	—
+ Dividends Paid	0.0	0.0	0.0	41.3	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	57.6	0.0	—
Cash from Financing Activities	-739.7	5.3	10,290.1	-2,952.7	—
Net Changes in Cash (pre-FX)	19.4	76.0	20.6	-27.8	—
+ Effect of FX Rate Changes on Cash	2.3	1.2	1.3	15.6	—
Net Changes in Cash	21.8	77.2	21.9	-12.2	—
Closing Cash	304.8	382.0	—	391.7	—
Reference Items
EBITDA	1,900.6	2,535.1	3,017.9	3,617.4	4,076.8
EBITDA Margin %	21.72	24.53	24.72	25.34	26.51
Free Cash Flow (CFO − Capex)	981.2	1,770.1	1,893.3	2,384.1	2,384.1
Free Cash Flow to Equity	—	1,781.5	10,100.8	-479.5	—
Free Cash Flow per Basic Share	23.77	42.88	45.86	57.75	57.75
Price to Free Cash Flow	—	—	—	—	43.11
Cash Flow to Net Income	1.38	1.11	1.20	1.61	—
Cash Paid for Taxes	323.1	479.5	566.8	592.7	—
Cash Paid for Interest	41.5	25.4	96.7	663.6	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.